181/892US=23-E / Câncer
Rübben A. Neurofibromatosis type 1-associated malignant melanoma: molecular evidence of inactivation of the NF1 gene. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 301-9. ISBN 978-90-481-2917-1.

NEUROFIBROMATOSE TIPO 1; MELANOMA MALIGNO; EVIDENCIA MOLECULAR DE INATIVACAO DO GENE NF1


182/892US=23-E / Câncer
Gheysens O, Mottaghy FM. Malignant melanoma: localisation and characterization using fluorodeoxyglucose-positron emission tomography/computed tomography. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 311-22. ISBN 978-90-481-2917-1.

MELANOMA MALIGNO; FLUORODESOXIGLICOSE POR EMISSAO DE POSITRONS; TOMOGRAFIA COMPUTADORIZADA


183/892US=23-E / Câncer
Roesch A, Landthaler M, Vogt T. Malignant melanoma versus deep penetrating nevus:diagnostic and prognostic immunohistochemistry of dipeptidy1 peptidase IV (methodology). In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 323-31. ISBN 978-90-481-2917-1.

MELANOMA MALIGNO; IMUNO-HISTOQUIMICA; DIPEPTIDE; PEPTIDASE IV; DIPEPTIDIL PEPTIDASE-4; DPP4


184/892US=23-E / Câncer
Hafner C. Nonmelanoma skin cancer use of Epha1 receptor as a prognostic marker. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 333-40. ISBN 978-90-481-2917-1.

CANCER DE PELE; EPHA1 RECEPTOR


185/892US=23-E / Câncer
Fiegl M, Mayer J. Pretreated chronic lymphocytic leukemia: use of alemtuzumab. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 343-58. ISBN 978-90-481-2917-1.

LEUCEMIA CRONICA. TRATAMENTO; LINFOCITICA; TRATAMENTO COM USO DE ALEMTUZUMAB


186/892US=23-E / Câncer
Chatterjee M, Manivannan R, Pande A, Chakraborty T. Immunotherapeutic strategies, radiotherapy, and targeted radionuclide therapy approaches for the treatment of multiple myeloma. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 361-82. ISBN 978-90-481-2917-1.

ESTRATEGIAS DE IMUNOTERAPIA; RADIOTERAPIA; TERAPIA; RADIONUCLIDEOS PARA O TRATAMENTO DO MIELOMA MULTIPLO


187/892US=23-E / Câncer
Matsuyama A, Hisaoka M, Hashimoto H. Low grade fibromyxoid sarcoma: diagnosis by detecting FUS-CREB3L2 fusion gene using reverse transcription-polymerase chain reaction. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 387-92. ISBN 978-90-481-2917-1.

SARCOMA DE BAIXO GRAU FIBROMIXOIDE; FUS-CREB3L2; GENE DE FUSAO. REACAO EM CADEIA DE POLIMERASE


188/892US=23-E / Câncer
Terry J, Nielsen TO. Synovial sarcoma: role of TLE1 as a diagnostic immunohistochemical marker. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 393-403. ISBN 978-90-481-2917-1.

SARCOMA SINOVIAL; TLE1 COMO MARCADOR; IMUNO-HISTOQUIMICA. DIAGNOSTICO


189/892US=23-E / Câncer
Pantanowitz L, Caponetti G, Dezube BJ. The immunohistochemistry of Kaposi's sarcoma. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 405-31. ISBN 978-90-481-2917-1.

IMUNO-HISTOQUIMICA DE SARCOMA DE KAPOSI; SARCOMA DE KAPOSI


190/892US=23-E / Câncer
Horvai AE. Synovial sarcoma: role of immunohistochemistry and molecular of immunohistochemistry and molecular genetics in diagnosis and prognosis. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 433-47. ISBN 978-90-481-2917-1.

SARCOMA SINOVIAL. DIAGNOSTICO; SARCOMA SINOVIAL. PROGNOSTICO


191/892US=23-E / Câncer
Fayette J, Cassier P, Brousseau L, Dufresne A, Coquard IR, Alberti L, Méeus P, Decouvelaere AV, Sunyach MP, Ranchère D, Bla JY. Sarcoma: treatment with ecteinascidin-743. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 451-60. ISBN 978-90-481-2917-1.

SARCOMA; TRATAMENTO COM ECTEINASCIDIN-743


192/892US=23-F / Câncer
Albrecht H. Role of antibodies in cancer treatment (an overview). In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 135-52. ISBN 978-90-481-3185-3.

TRATAMENTO DO CANCER; ANTICORPOS NO TRATAMENTO DO CANCER


193/892US=23-F / Câncer
Lee W, Lockhart AC. Incorporating pharmacogenomics into cancer therapy. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 153-72. ISBN 978-90-481-3185-3.

FARMACOGENOMICA EM TERAPIA DO CANCER


194/892US=23-F / Câncer
Morii E, Aozasa K. Cancer stem cells: an overview. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 173-81. ISBN 978-90-481-3185-3.

CANCER DE CELULAS-TRONCO; ISOLAMENTO DO CANCE DE CELULAS-TRONCO


195/892US=23-F / Câncer
Mehta JP, O'Driscoll L, Barron N, Clynes M, Doolan P. Translating in vitro cell lines result into clinical practice. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 183-91. ISBN 978-90-481-3185-3.

LINHAGENS DE CELULAS


196/892US=23-F / Câncer
Pellegrini P, Contasts AM, Berghella AM, Del Beato T. Adorno D. Classification of cancer stange using patient's Immune system. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 195-213. ISBN 978-90-481-3185-3.

CLASSIFICACAO DE CANCER; SISTEMA IMUNITARIO DO PACIENTE COM CANCER


197/892US=23-F / Câncer
Oldenburg J, Fossa SD. Late relapse of germ cell malignancies: incidence, management, and prognosis. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 215-26. ISBN 978-90-481-3185-3.

RECAIDA TARDIA DE TUMORES MALIGNOS DE CELULAS GERMINATIVAS; TUMORES MALIGNOS DE CELULAS GERMINATIVAS. PROGNOSTICO


198/892US=23-F / Câncer
Stack Jr BC, Clarke B, McElderry J, Dai Y, Ye JH. Head and neck squamous cell carcinoma: therapy with fusaric acid/paclitaxel. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 229-35. ISBN 978-90-481-3185-3.

CARCINOMA DE CELULAS ESCAMOSAS; TERAPIA COM ACIDO FUSARICO / PACLITAXEL


199/892US=23-F / Câncer
Shah NG, Trivedi TI. Early stage oral squamous cell carcinoma: use of signal transducer and activator of transcription 3 as a risk factor for poor diagnosis. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 237-53. ISBN 978-90-481-3185-3.

CARCINOMA DE CELULAS ESCAMOSAS ORAL; USO DE TRANSDUTOR DE SINAL; FATOR 3 ATIVADOR DA TRANSCRICAO


200/892US=23-F / Câncer
Nakamura T, Sumi M, Cauteren MV. Salivary gland tumors: preoperative tissue characterization with apparent diffusion coefficient mapping. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods, overviews, head and neck cancer, and thyroid cancer. New York: Springer, 2010. p. 255-69. ISBN 978-90-481-3185-3.

TUMORES DAS GLANDULAS SALIVARES; TECIDUAL PRE-OPERATORIO COM MAPEAMENTO


Primeira | Anterior | Próxima | Última